Latest News for: kinases

Edit

How plants fend off pathogens: The role of calcium and kinases

Phys Dot Org 27 Jan 2025
Kudla's team showed for the first time that two different kinases, both of which are activated by calcium, have to work together in order to facilitate efficient systemic immune signal proliferation.
Edit

Marketing Authorization for the Oral Spleen Tyrosine Kinase Inhibitor TAVALISSE® in South Korea (Kissei Pharmaceutical Co Ltd)

Public Technologies 21 Jan 2025
Announcement of in-licensing of technology related to a small molecule tyrosine kinase inhibitor fostamatinib ... Sub-licensing Agreement for Spleen Tyrosine Kinase Inhibitor "Fostamatinib (R788)" with JW Pharmaceutical Corporation.
Edit

Global Kinase Inhibitor in Autoimmune Diseases Market Size is anticipated to witness growth at a ...

GetNews 02 Jan 2025
Discover Key Insights into the Global Kinase Inhibitor in Autoimmune Diseases Market with DelveInsight's In-Depth Report @. Key Takeaways from the Kinase Inhibitor in Autoimmune Diseases Market Research Report.
Edit

Dual-action kinase inhibitors influence p38α MAP kinase dephosphorylation

PNAS 31 Dec 2024
Many kinases are switched on by phosphorylation of their dynamic ...
Edit

Leveraging Recombinant Kinases for Drug Discovery Research

The Scientist 27 Dec 2024
As kinase dysfunction underlies many pathological conditions, scientists require high-quality active kinases for their therapeutic development programs ... .
Edit

Dizal Announces Positive Pooled Data of Sunvozertinib in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung ...

My Horry News 12 Dec 2024
Sunvozertinib, as a single agent, demonstrated promising antitumor activity and favorable safety profile in heavily pretreated patients with EGFR-mutated NSCLC who had developed resistance to EGFR TKI treatment ....
Edit

Imetelstat Versus Best Available Therapy in Patients with Intermediate 2 or High Risk Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitor in IMpactMF, a Randomized Open Label, Phase 3 Trial (Geron Corporation)

Public Technologies 08 Dec 2024
to Janus Kinase Inhibitor in IMpactMF, a Randomized, Open-label, Phase 3 Trial ... • While Janus kinase inhibitors (JAKi) have transformed therapy in MF, ultimately patients either relapse or become refractory to JAKi and have poor survival rates.
Edit

Tyrosine Kinase Inhibitors Market to Grow by USD 24.22 Billion (2024-2028), Fueled by High Target ...

Longview News-Journal 02 Dec 2024
NEW YORK, Dec. 2, 2024 /PRNewswire/ -- Report with market evolution powered by AI - The global tyrosine kinase inhibitors market size is estimated to grow by USD 24.22 billion from 2024-2028, according to Technavio. The market is estimated to ....
Edit

Tyrosine Kinase Inhibitors Market to Grow by USD 24.22 Billion (2024-2028), Fueled by High Target Affinity, with AI Transforming Market Trends - Technavio

PR Newswire 02 Dec 2024
2, 2024 /PRNewswire/ -- Report with market evolution powered by AI - The global tyrosine kinase inhibitors market size is estimated to grow by USD 24.22 billion from 2024-2028, according to Technavio ... Tyrosine Kinase Inhibitors Market Scope.

Most Viewed

×